LIVE WEBINAR: Wednesday, February 3, 2021, 5:00 PM – 6:00 PM Eastern Time

Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting

Part 2 - Hodgkin and Non-Hodgkin Lymphoma

Faculty

John Kuruvilla, MD
Hematologist, Princess Margaret Cancer Centre
Associate Professor, University of Toronto
Toronto, Ontario, Canada

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
Weill Cornell Medicine
New York, New York



Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
Physician Lead, Cancer Service Line
University of Virginia School of Medicine
Charlottesville, Virginia

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics and Seagen Inc.

Wednesday, February 3, 2021
5:00 PM – 6:0 PM Eastern Time
Live CME-accredited webinar

Topics to Be Discussed

  • Evolving treatment paradigm for patients with diffuse large B-cell lymphoma (DLBCL)
  • Optimal management of newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL)
  • Available and emerging approaches for mantle cell lymphoma (MCL)
  • Selection and sequencing of therapies for patients with advanced Hodgkin lymphoma (HL)
  • Advances in chimeric antigen receptor T-cell therapy for DLBCL and other lymphoma subtypes

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall published research data and other clinical factors in the best-practice selection, sequencing or combination of available therapeutic agents and strategies in the care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of newly diagnosed and R/R mantle cell lymphoma (MCL) to determine the current and potential utility in clinical practice.
  • Incorporate new therapeutic agents and strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Consider age, performance status and other clinical and biologic factors in the selection of up-front and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL).
  • Develop an understanding of the biologic rationale for and appreciate the available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R B-cell lymphomas for whom this approach may be appropriate.
  • Design a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of FL, MCL, HL and DLBCL to support quality of life and continuation of therapy.
  • Recall new data with investigational agents and strategies demonstrating promising activity in various lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr KuruvillaConsulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Seagen Inc; Honoraria: Amgen Inc, Antengene, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, TG Therapeutics Inc. Dr LeonardConsulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MEI Pharma Inc, MorphoSys, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company. Dr WilliamsAdvisory Committee: AbbVie Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Speakers Bureau: Xian Janssen Pharmaceutical Ltd.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics and Seagen Inc.